Indirect treatment comparison of iptacopan versus pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and residual anemia despite C5 inhibitor treatment
Journal of Comparative Effectiveness Research · 2026-04 · 15 (4)
DOI: 10.57264/cer-2025-0167 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Comparative Effectiveness Research, 2026-04. Verfasst von Austin Kulasekararaj und 9 weiteren Autor:innen. Beteiligte Einrichtung: King's College Hospital NHS, London, UK. Hauptthemen laut MEDLINE: Hemoglobinuria, Paroxysmal, Polyethylene Glycols, Anemia, Complement C3. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
This study conducted an indirect treatment comparison (ITC) of iptacopan, the first oral monotherapy targeting factor B, versus pegcetacoplan, a subcutaneous infusion targeting complement component 3, in patients with paroxysmal nocturnal hemoglobinuria (PNH) and residual anemia despite complement component 5 inhibitors (C5i). An unanchored matching adjusted ITC was performed, using phase III APPLY-PNH and PEGASUS studies, identified by a systematic literature review. The outcomes were: change from baseline (CfB) in hemoglobin (Hb), with and without post-transfusion data, CfB in lactate dehydrogenase (LDH), CfB in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue score, transfusion avoidance, and serious adverse events. Two adjustment scenarios were analyzed: (A) baseline Hb, sex, transfusion history ≤12 months, and (B) scenario A plus reticulocyte count, baseline LDH and age. After matching and adjusting, baseline characteristics were similar across trials. Iptacopan showed greater Hb improvements than pegcetacoplan with post-transfusion data (mean difference – scenario A: 1.05 g/dl; p < 0.001, scenario B: 0.76 g/dl; p = 0.018) and without (A: 1.31 g/dl; p < 0.001, B: 1.01 g/dl; p = 0.014). Odds of transfusion avoidance were higher with iptacopan (A: odds ratio [OR] = 9.17, p = 0.013; B: OR = 12.71, p = 0.009). No significant difference was noted in CfB in LDH and FACIT-Fatigue score. These findings suggest that iptacopan may improve Hb levels and reduce transfusion dependency compared with pegcetacoplan in PNH patients with residual anemia despite C5i and must be interpreted in the context of ITCs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- King's College Hospital NHS, London, UK.
- National Institute for Health & Care Research & Wellcome King's Research Facility, London, UK.
- King's College London, London, UK.
- Hospital A Beneficência Portuguesa, São Paulo, Brazil.
- Novartis Pharma AG, Basel, Switzerland.
- Novartis Pharmaceuticals UK Ltd, London, UK.
ORCID-Profile: Austin Kulasekararaj, Phillip Scheinberg, Maria-Magdalena Balp, Olivier Somenzi, Anggie Wiyani, Josefin Snellman, Sarah Walsh, Katharina Pannagl, Jason Steenkamp, Régis Peffault de Latour
Zitieren
APA
Kulasekararaj, A., Scheinberg, P., Balp, M. M., Somenzi, O., Wiyani, A., Snellman, J., Walsh, S., Pannagl, K., Steenkamp, J., & de Latour, R. P. (2026). Indirect treatment comparison of iptacopan versus pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and residual anemia despite C5 inhibitor treatment. Journal of Comparative Effectiveness Research, 15(4). https://doi.org/10.57264/cer-2025-0167
Vancouver
Kulasekararaj A, Scheinberg P, Balp MM, Somenzi O, Wiyani A, Snellman J, et al. Indirect treatment comparison of iptacopan versus pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and residual anemia despite C5 inhibitor treatment. Journal of Comparative Effectiveness Research. 2026;15(4). doi:10.57264/cer-2025-0167
BibTeX
@article{Kulasekararaj2026,
author = {Kulasekararaj, Austin and Scheinberg, Phillip and Balp, Maria-Magdalena and Somenzi, Olivier and Wiyani, Anggie and Snellman, Josefin and Walsh, Sarah and Pannagl, Katharina and Steenkamp, Jason and de Latour, Régis Peffault},
title = {Indirect treatment comparison of iptacopan versus pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and residual anemia despite C5 inhibitor treatment},
journal = {Journal of Comparative Effectiveness Research},
year = {2026},
volume = {15},
number = {4},
doi = {10.57264/cer-2025-0167}
}
EUVIMED